1)原田一道.急性胃粘膜病変の成因.胃と腸 24:637-644, 1989
2)溝上裕士,谷田憲俊,西村正二,他.慢性関節リウマチ患者における上部消化管病変の内視鏡学的検討について.Gastroenterol Endosc 28:2297-2305, 1986
3)塩川優一,延永正,斉藤輝信,他.非ステロイド性抗炎症剤のよる上部消化管障害に関する疫学調査.リウマチ 31:96-111, 1991
4)粒良邦彦,星原芳雄,森藤忠夫,他.膠原病およびその類似疾患に対するステロイド,非ステロイド系抗炎症剤の長期投与中に見られた胃潰瘍について.Gastroenterol Endosc 26:377-404, 1984
5)菅野健太郎.胃炎と胃潰瘍へのアプローチ―ヘリコバクター・ピロリ除菌時代の消化性潰瘍の治療戦略.Medical Practice 18:1954-1960, 2001
6)太田慎一,新井晋,今井幸紀,他.H. pylori陰性潰瘍―NSAID潰瘍.臨床消化器内科 19:529-537, 2004
7) Nakashima S, Arai S, Mizuno Y, et al. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 21(Suppl 2):60-66, 2005
8) Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis. BMJ 321:1183-1187, 2000
9) Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348:1413-1416, 1996
10) Cryer B, Feldman M, Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117:17-25, 1999
11) Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 16:1945-1953, 2002
12) Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 95:2218-2224, 2000
13) Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343:834-839, 2000
14) Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528, 2000
15) Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000
16) Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959, 2001
17)溝上裕士,白石貴久,大坪十四哉,他.NSAIDs長期投与慢性関節リウマチ患者における胃潰瘍についての臨床的検討.Clin Rheumatol 10:130-141, 1998
18)中村孝司,屋嘉比康治,黒沢進,他.NSAID胃粘膜障害の臨床.臨床消化器内科 14:403-412, 1999
19)溝上裕士.NSAIDs長期投与による潰瘍発生.消化器科 14:513-519, 1991
20)前田淳,田中良基,秋本真寿美,他.NSAID胃病変の内視鏡診断.臨床消化器内科 14:419-424, 1999
21) Mizokami Y, Tamura K, Fukuda Y, et al. Non-steroidal anti-inflammatory drugs associated with gastroduodenal injury and Helicobacter pylori. Eur J Gastroenterol Hepatol 6(Suppl 1):S109-112, 1994
22) Taha AS, Nakshabendi I, Lee FD et al. Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti inflammatory drugs. J Clin Pathol 45:135-139, 1992
23) Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology 100:1653-1657, 1991
24) Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease:a meta-analysis. Lancet 359:14-22, 2002
25) Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62:765-772, 2006
26) Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low dose aspirin or naproxen. N Engl J Med 344:967-973, 2001
27)胃潰瘍ガイドラインの適用と評価に関する研究班(編).EBMに基づく胃潰瘍診療ガイドライン,2版.じほう,p 89,2007